CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03040713
NCT03040713Phase 1Completed
CompareCT.gov

18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia

Avid Radiopharmaceuticals·interventional·Posted Feb 2, 2017·Updated Sep 25, 2020

In Brief

A Phase 1 clinical trial evaluating Flortaucipir F18 and Brain PET scan for Frontotemporal Dementia. Completed, enrolled 16 participants across 3 sites.

Detailed Summary

This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrontotemporal Dementia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2, 2017
Enrollment StartApr 11, 2017
Primary CompletionOct 24, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.4 years ago

Interventions

Flortaucipir F18drug

370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose

Brain PET scanprocedure

positron emission tomography (PET) scan of the brain